Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niaspan plus fluvastatin versus fluvastatin monotherapy in metabolic syndrome
2005-003812-31Phase 2Completed
- Sponsor
- University Hospital Freiburg
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of niacin and fluvastatin in cardiometabolic risk (CMR) and dyslipidemia (2 arms), sponsored by University Hospital Freiburg. Primary endpoint: Change in apoB concentration in dense LDL subfractions. Started Oct 2006; status: completed.
02
Drugs
niacinfluvastatin
03
Conditions
cardiometabolic risk (CMR)dyslipidemia
Beyond the preview
Go deeper on 2005-003812-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003812-31.